Page 15 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activating construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activating Construct Today - Breaking & Trending Today

Zacks Investment Research Lowers Harpoon Therapeutics (NASDAQ:HARP) to Hold

Zacks Investment Research lowered shares of Harpoon Therapeutics (NASDAQ:HARP – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of […] ....

United States , San Francisco , Schonfeld Strategic Advisors , Harpoon Therapeutics Inc , Goldman Sachs Group Inc , Zacks Investment Research , Parametric Portfolio Associates , Wells Fargo Company , Harpoon Therapeutics Company Profile Get Rating , Barclays Plc , Harpoon Therapeutics , Get Rating , Activating Construct , Sachs Group , Portfolio Associates , Strategic Advisors , Therapeutics Company Profile , Nasdaq Harp ,

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 07, 2022 Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and. | March 7, 2022 ....

United States , Roberth Uhl , Julie Eastland , Exchange Commission , Harpoon Therapeutics Inc , Drug Administration , Orphan Drug Designation , Drug Designation , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic , Nc Stock Exchange , Press Release , Ood Harp Us41358p1066 ,

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United States , Roberth Uhl , Exchange Commission , Harpoon Therapeutics Inc , American Society For Hematology , International Myeloma Working Group , Harpoon Therapeutics , American Society , Annual Meeting , Activating Construct , Natalie Sacks , Chief Medical Officer , Dose Escalation , Dose Expansion Study , Patients With , Combination Therapeutics , Anti Tumor Activity , Webcast Details , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United States , Roberth Uhl , Kathryns Kwant , Harpoon Therapeutics Inc , Harpoon Therapeutics , Annual Meeting , Novel Single Agent , Presentation Date , Activating Construct ,

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting

Investegate announcements from Arix Bioscience PLC, Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting ....

United States , City Of , United Kingdom , Supriya Mathur , Charlotte Parry , Roberth Uhl , Shabnam Bashir , Jerry Mcmahon , Mary Clark , Arix Bioscience , Exchange Commission , Strategic Communications , Harpoon Therapeutics Inc , American Society Of Clinical Oncology , Harpoon Therapeutics , Clinical Oncology , Activating Construct , Natalie Sacks , Chief Medical Officer , Interim Results , Limiting Toxicities , Maximum Tolerated Dose , Advanced Prostate , Private Securities Litigation Reform Act , Harpoon Therapeutic , Investegate Announcements ,